Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma Research Letter
| Authors: | Jaeger, U.; Tam, C. S.; Borchmann, P.; McGuirk, J. P.; Johansen, M.; Waller, E. K.; Jaglowski, S.; Andreadis, C.; Foley, S. R.; Westin, J. R.; Fleury, I.; Ho, P. J.; Mielke, S.; Teshima, T.; Salles, G.; Schuster, S. J.; He, F.; Maziarz, R. T.; Mayer, S.; Makita, S.; Kersten, M. J.; Ghosh, M.; Wagner-Johnston, N.; Kato, K.; Corradini, P.; Goto, H.; Colicino, S.; Agarwal, A.; Lobetti-Bodoni, C.; Bishop, M. R. |
| Title: | Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma |
| Keywords: | disease course; neutropenia; drug safety; note; cancer patient; rituximab; follow up; cancer diagnosis; cancer incidence; infection; breast cancer; anemia; thrombocytopenia; lymphocytopenia; prostate cancer; disease severity; drug response; patient safety; blood transfusion; kaplan meier method; immunoglobulin deficiency; granulocyte colony stimulating factor; cytopenia; clinical trial (topic); diffuse large b cell lymphoma; human; tisagenlecleucel t |
| Journal Title: | Blood Advances |
| Volume: | 6 |
| Issue: | 16 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-08-23 |
| Start Page: | 4816 |
| End Page: | 4820 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2021006193 |
| PUBMED: | 35687492 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Export Date: 3 October 2022 -- Source: Scopus |
